turk j diab obes

Turkish Journal of Diabetes and Obesity

2587-0335 2587-0572

Zonguldak Bulent Ecevit University

10.25048/tudod.1433198

Endocrinology Physiopathology Medical Physiology (Other)

Endokrinoloji Fizyopatoloji Tıbbi Fizyoloji (Diğer)

Polikistik Over Sendromlu Hastalarda Insülin Direnci ile Sempatik Deri Cevabı Arasındaki Ilişki

The Relation Between Insulin Resistance and Sympathetic Skin Response in Patients with Polycystic Ovary Syndrome

https://orcid.org/0000-0002-3104-7587

Dolu

Nazan

ISTANBUL MEDIPOL UNIVERSITY, SCHOOL OF MEDICINE

https://orcid.org/0000-0001-5965-0591

Batir

Setenay

KAYSERI UNIVERSITY, KAYSERİ VOCATIONAL SCHOOL

https://orcid.org/0000-0003-4923-5751

Turan

Tayfun

ERCIYES UNIVERSITY, SCHOOL OF MEDICINE

https://orcid.org/0000-0002-9637-6744

Bayram

Fahri

ERCIYES UNIVERSITY, SCHOOL OF MEDICINE

04 30 2025

9 1 19 26 11 11 2024 04 13 2025

2017

Turkish Journal of Diabetes and Obesity

Amaç: Polikistik over sendromunda (PCOS) görülen hipertansiyon ve insülin direnci gibi bozukluklardan sempatik aktivitedeki değişiklikler sorumludur. Sempatik deri cevabı (SDC), sempatik sinirler tarafından uyarılan sudomotor bezlerin aktivitesini yansıtır. Bu çalışmada, PKOS hastalarında insülin direnci ile SSR arasındaki ilişkiyi araştırmayı amaçladık. Ayrıca antidiyabetik ajan metformin ile insülin direnci tedavisinin SSR üzerindeki etkisi araştırıldı.Gereç ve Yöntemler: Çalışmaya metformin tedavisi almayan insülin direnci olan 30 PKOS hastası ve 20 sağlıklı kadın dahil edildi. Tüm katılımcılara hormon, oral glukoz tolerans testi ve HOMA skoru (Homeostasis Model Assessment) ölçümleri yapıldı. SSR'nin bir parametresi olan ve sempatik aktiviteyi yansıtan deri iletkenlik seviyesi (DİS), anksiyete-depresyon olmayan tüm katılımcılardan kaydedildi. PKOS hastalarında 6 ay süreyle 1500-2000 mg/gün metformin tedavisi sonrasında tüm ölçümler tekrarlandı.Bulgular: Testosteron ve androstenedion düzeyleri ile HOMA-insülin direnci değerleri PKOS'lu hastalarda sağlıklı kontrollere göre anlamlı derecede yüksekti (p

Aim: Changes in sympathetic activity are responsible for disorders such as hypertension and insulin resistance observed in polycystic ovary syndrome (PCOS). The Sympathetic skin response (SSR) reflects the activity of the sudomotor glands stimulated by the sympathetic nerves. In this study, we aimed to investigate the relationship between insulin resistance and SSR in PCOS patients. In addition, the effect of insulin resistance treatment with the antidiabetic agent metformin on SSR was explored.Material and Methods: Thirty PCOS patients with insulin resistance who did not receive metformin therapy and twenty healthy women were included in the study. Hormone, oral glucose tolerance test, and HOMA score (Homeostasis Model Assessment) measurements were performed on all participants. Skin conductance level (SCL) which is a parameter of SSR and reflects sympathetic activity was recorded from the all participants without anxiety-depression. All measurements were repeated after treatment with 1500-2000 mg/day metformin for 6 months in PCOS patients.Results: Testosterone, and androstenedione levels, HOMA-insulin resistance values were significantly higher in PCOS patients than healthy controls (p

Polycystic Ovary Syndrome sympathetic skin response insulin resistance sympathetic activity HOMA

Polikistik over sendromu Sempatik deri cevabı İnsülin direnci sempatik aktivite

This study was supported by Erciyes University Research Fund (TSY-10-3284).

TSY-10-3284

1. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): ar guably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999; 84:1897-1899.

2. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985; 61:946-51.

3. Azziz R, Ehrmann D, Legro RS, et al. PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001; 86:1626-1632.